4-bromo-4'-(bromomethyl)-1,1'-biphenyl | 50670-57-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-bromo-4'-(bromomethyl)-1,1'-biphenyl
• 英文别名: 4-Bromomethyl-4'-bromobiphenyl；4'-bromo-4-bromomethyl-biphenyl；1-bromo-4-[4-(bromomethyl)phenyl]benzene
• CAS: 50670-57-0
• 化学式: C₁₃H₁₀Br₂
• 分子量: 326.03
• InChiKey: AJHADXHEAFCOTE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  4-bromo-4'-(bromomethyl)-1,1'-biphenyl 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 反应 1.0h， 生成 4'-bromo-(1,1'biphenyl)-4-methanol
  参考文献：
  名称：

  Conformationally restricted retinoids

  摘要：

  A series of conformationally restricted retinoids was synthesized and screened in two assays used to measure the ability of retinoids to control cell differentiation, namely, the reversal of keratinization in tracheal organ culture from vitamin A deficient hamsters and the inhibition of the induction of mouse epidermal ornithine decarboxylase by a tumor promoter. These compounds had bonds corresponding to selected bonds of the E-tetraene chain of retinoic acid (1) held in a planar cisoid conformation by inclusion in an aromatic ring. The meta-substituted analogue 3 of 4-[(E)-2-methyl-4-(2,6,6-trimethylcyclohexenyl)-1,3-butadienyl+ ++]benzoic acid (2) was far less active than 2 in both assays. In contrast, the vinyl homologue of 2 (4) and the 7,8-dihydro and 7,8-methano analogues (5 and 6) had activity comparable to that of 2. Analogues of 4-[(E)-2-(1,1,4,4-tetramethyl-1,2,3,4-tetrahydro-6-naphthyl)propenyl] benzoic acid (7) were also screened. Replacement of the tetrahydronaphthalene ring of 7 by a benzonorbornenyl group (9) significantly reduced activity, as did removal of the vinylic methyl group from 9 (10). Replacement of the propenyl group of 9 by a cyclopropane ring (12) also reduced activity. Replacement of the tetrahydronaphthalene ring of 7 by 4,4-dimethyl-3,4-dihydro-2H-1-benzopyran and -benzothiopyran rings (13 and 14) also decreased activity. Inclusion of the 7,9 double bond system of 1 in an aromatic ring (15 and 16) reduced activity, whereas inclusion of the 5,7 double bond system in an aromatic ring enhanced activity (7 and 19). Inclusion of the 11,13 and 9,11,13 double bond systems in aromatic rings (2 and 18) also reduced activity below that of 1. Retinoic acid, 7, 13, 14, and 19 inhibited papilloma tumor formation in mice. Toxicity testing indicated that 7 was more toxic than 1, 13, 14, and 19, 19 was more toxic than 1, and 13 and 14 were less toxic than 1.

  DOI：

  10.1021/jm00377a022
• 作为产物：
  描述：

  4-溴苯硼酸 在 四(三苯基膦)钯 lithium aluminium tetrahydride 、 sodium carbonate 、 二溴三苯基膦 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成 4-bromo-4'-(bromomethyl)-1,1'-biphenyl
  参考文献：
  名称：

  [EN] SUBSTITUTED AMINO CARBOXYLIC ACIDS AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE-1B
  [FR] ACIDES AMINO-CARBOXYLIQUES SUBSTITUES

  摘要：

  公开号：

  WO2004099171A3

文献信息

• Method and compositions for identifying anti-HIV therapeutic compounds
  申请人：Arimilli N. Murty

  公开号：US20050239054A1

  公开（公告）日：2005-10-27

  Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

  提供了一种识别含有羧酸酯或磷酸酯基团取代的抗HIV治疗化合物的方法。可以选择使用新型酶GS-7340酯水解酶对这类化合物库进行筛选。还提供了与GS-7340酯水解酶相关的组合物和方法。
• Functionalised phosphonate ester supported lanthanide (Ln = La, Nd, Dy, Er) complexes
  作者：Ingo Koehne、Artur Lik、Miriam Gerstel、Clemens Bruhn、Johann Peter Reithmaier、Mohamed Benyoucef、Rudolf Pietschnig

  DOI：10.1039/d0dt03047c

  日期：——

  A series of phosphonate ester supported lanthanide complexes bearing functionalities for subsequent immobilisation on semi-conductor surfaces have been prepared. Six phosphonate ester ligands (L1-L6) with varying aromatic residues were synthesised. Subsequent complexation with lanthanide chloride or -nitrate precursors (Ln = La, Nd, Dy, Er) afforded the corresponding mono- or dimeric lanthanide model

  已经制备了一系列具有官能度的膦酸酯负载的镧系元素络合物，这些官能团随后可固定在半导体表面上。合成了具有不同芳族残基的六个膦酸酯配体（L1-L6）。随后与氯化镧或硝酸根前驱物（Ln = La，Nd，Dy，Er）络合，得到相应的单或二聚镧系元素模型络合物[LnX3（L1-L3或L5-L6）3] n（X = NO3，Cl ; n = 1（Nd，Dy，Er），2（La，Nd））或[LnCl2Br（L4-Br）2（L4-Cl）] n（n = 1（Nd，Dy，Er），2（La ，Nd））（1-32）。对所有化合物进行了全面表征，并在适用的情况下在可见光和NIR光谱区域中研究了它们的发光特性。
• Substituted amino carboxylic acids
  申请人：Whitehouse Darren

  公开号：US20060122223A1

  公开（公告）日：2006-06-08

  Disclosed are compounds and pharmaceutically acceptable salts of formula (I): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明揭示了公式（I）的化合物及其药学上可接受的盐，它们可用于治疗与胰岛素抵抗、瘦素抵抗或高血糖相关的代谢性疾病。本发明的化合物包括蛋白酪氨酸磷酸酶抑制剂，特别是蛋白酪氨酸磷酸酶-1B（PTP-1B），它们可用于治疗糖尿病和其他PTP介导的疾病，如癌症、神经退行性疾病等。本发明还揭示了包括本发明化合物的制药组合物以及使用这些化合物治疗上述疾病的方法。
• Phenyl substituted carboxylic acids
  申请人：Van Zandt C. Michael

  公开号：US20060122257A1

  公开（公告）日：2006-06-08

  Disclosed are compounds and pharmaceutically acceptable salts of formula (A): which are useful in the treatment of metabolic disorders related to insulin resistance, leptin resistance, or hyperglycemia. Compounds of the invention include inhibitors of Protein tyrosine phosphatases, in particular Protein tyrosine phosphatase-1B (PTP-1B), that are useful in the treatment of diabetes and other PTP mediated diseases, such as cancer, neurodegenerative diseases and the like. Also disclosed are pharmaceutical compositions comprising compounds of the invention and methods of treating the aforementioned conditions using such compounds.

  本发明揭示了公式（A）的化合物及其药学上可接受的盐，其在治疗与胰岛素抵抗、瘦素抵抗或高血糖相关的代谢性疾病方面具有用途。本发明的化合物包括蛋白酪氨酸磷酸酶的抑制剂，特别是蛋白酪氨酸磷酸酶-1B（PTP-1B），这些抑制剂在治疗糖尿病和其他PTP介导的疾病（如癌症、神经退行性疾病等）方面具有用途。本发明还揭示了包括本发明化合物的制药组合物以及使用这些化合物治疗上述疾病的方法。
• Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds
  申请人：Arimilli N. Murty

  公开号：US20050209197A1

  公开（公告）日：2005-09-22

  Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

  本发明揭示了具有抗HIV蛋白酶活性的膦酸酯取代化合物，可用作治疗剂和其他工业用途。该组合物抑制HIV蛋白酶活性和/或在治疗艾滋病和其他抗病毒感染方面有用，以及在检测HIV蛋白酶的测定中有用。